ABOUT US

AlaMab is a clinical stage biopharmaceutical company focused on commercializing novel monoclonal antibody therapeutics to benefit patients suffering from indications with significant unmet treatment needs. AlaMab was founded in 2017 and is led by a skilled management and advisory team with substantial experience in antibody and pharmaceutical development.

Leadership Team

Qingxi (Charles) Wang PhD — Chairman & CEO

Dr. Qingxi (Charles) Wang serves as a Director on the Board and Executive President of CSPC Pharmaceutical Group, Ltd. He is also President of the CSPC International Division. Dr. Wang holds a PhD in Chemistry from the University of Connecticut, and an MBA from Temple University. Prior to joining the Group, Dr. Wang worked at Merck & Co., Inc. in the U.S. for over 20 years, where he held senior positions including Director of Pharmaceutical R&D and Managing Director of Business Development and Operation. He is responsible for business development and the overall management of AlaMab.

Yanfeng Zhang PhD — President

Dr. Yanfeng Zhang completed his PhD in Genetics/Biochemistry from Michigan State University and post-doctoral studies at Pacific Northwest National Laboratory and University of Texas Health Science Center at San Antonio. He has over ten years of combined industrial and academic experience in protein structure and function, manufacturing, and drug development. Before joining AlaMab, he was a Director at XBiotech. Dr. Zhang is responsible for the overall operation, pre-clinical development, and coordination of clinical trials of AlaMab.

Scientific Advisory Board

Daniel D. Von Hoff MD,FACP — Co-Chair

Dr. Daniel D. Von Hoff is currently Physician in Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute, and the Margaret Givan Larkin Endowed Chair in Developmental Cancer Therapeutics at Hoag Hospital. He is also the Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for U.S. Oncology Research specializing in Phase I clinical trials. Additionally, he is a Professor of Medicine at the University of Arizona and at the Mayo Clinic, Scottsdale, AZ, and a Senior Consultant of Clinical Investigation at the City of Hope. Prior to conducting his residency in internal medicine at UC San Francisco and a fellowship in oncology at the National Cancer Institute, Dr. Von Hoff attended Carroll College and Columbia University.

Dr. Von Hoff’s primary interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the early development stages of many FDA-approved agents now used routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, pexidartinib, and others. His clinical trial work has led to the approval of three of the four drugs currently approved by the FDA for the treatment of patients with advanced pancreatic cancer. At present, he and his colleagues are concentrating on the development of therapies for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 741 papers, 143 book chapters, and over 1186 abstracts. Dr. Von Hoff has received many awards throughout his career, including the 2010 American Society of Clinical Oncology (ASCO) David A. Karnofsky Memorial Award, the American Association for Cancer Research (AACR) Distinguished Public Service Award, the 2011 Scripps Genomic Medicine Award, 2014 Hope Funds for Cancer Research Award of Excellence, 2015 Wallace A. Reed MD Award, 2016 OncLive Giant of Cancer Care® designation, 2014 ASCO 50 Oncology Luminaries designation, and among the first class selected in 2013 by the AACR for its Fellows of the AACR Academy.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the AACR (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is a founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.